


Appendix AClaim Amendments

1. (Currently amended) A compound ~~Compounds~~ of the formula I,



in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, completely or predominantly  
fluorine-substituted 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl,  
hydroxy-2-4C-alkyl or 1-7C-alkylcarbonyl,

R5 is hydrogen or 1-4C-alkyl,

R6 is hydrogen, 1-4C-alkyl, trifluoromethyl, 1-4C-alkoxy,  
completely or predominantly fluorine-substituted 1-4C-  
alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, halogen,  
nitro, cyano, hydroxyl, 1-4C-alkylcarbonyloxy, amino, mono-  
or di-1-4C-alkylamino, phenyl, phenyl-1-4C-alkyl, 1-4C-  
alkylcarbonylamino, phenoxy or C(O)OR<sub>61</sub>, wherein

R61 is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-  
cycloalkylmethyl,

R7 is hydrogen, 1-4C-alkyl, hydroxyl, halogen, 1-4C-alkoxy,  
completely or predominantly fluorine-substituted 1-4C-  
alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or  
C(O)OR<sub>61</sub>,

~~and the salts, the N-oxides and the salts of the N-oxides of  
these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

2. (Currently amended) A compound ~~Compounds~~ of the formula I according to claim 1, in which

R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,

R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or completely or predominantly fluorine-substituted 1-4C-alkoxy,

or in which

R1 and R2 together are a 1-2C-alkylenedioxy group,

R3 is hydrogen or 1-4C-alkyl,

R31 is hydrogen or 1-4C-alkyl,

R4 is hydrogen, 1-4C-alkyl, completely or predominantly fluorine-substituted 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, ~~hydroxy-2-4-alkyl~~ hydroxy-2-4C-alkyl or 1-7C-alkylcarbonyl,

R5 is hydrogen or 1-4C-alkyl<sup>2</sup>,

R6 is hydrogen, 1-4C-alkoxy, trifluoromethyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, halogen,

nitro, cyano, hydroxyl, 1-4C-alkylcarbonyloxy, amino, mono-  
or di-1-4C-alkylamino, phenyl, phenyl-1-4C-alkyl, 1-4C-  
alkylcarbonylamino or C(O)OR<sub>61</sub>, wherein

R<sub>61</sub> is hydrogen, 1-7C-alkyl, 3-7C-cycloalkyl or 3-7C-  
cycloalkylmethyl,

R<sub>7</sub> is hydrogen, 1-4C-alkyl, hydroxyl, halogen, 1-4C-alkoxy,  
completely or predominantly fluorine-substituted 1-4C-  
alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy or  
C(O)OR<sub>61</sub>,

~~and the salts, the N-oxides and the salts of the N-oxides of  
these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a  
salt of this compound, an N-oxide of this compound, or a salt of  
an N-oxide of this compound.

3. (Currently amended) A compound ~~Compounds~~ of the formula I  
according to claim 1, in which

R<sub>1</sub> is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy,  
or completely or predominantly fluorine-substituted 1-2C-  
alkoxy,

R<sub>2</sub> is 1-2C-alkoxy, 3-5C-cycloalkoxy, 3-5C-cycloalkylmethoxy,  
or completely or predominantly fluorine-substituted 1-2C-  
alkoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is hydrogen, 1-4C-alkyl, 1-2C-alkoxy-2-4C-alkyl or 1-7C-alkylcarbonyl,

R5 is hydrogen,

R6 is 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkylmethoxy, halogen, nitro, cyano, hydroxyl, 1-4C-alkylcarbonyloxy, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, phenoxy or C(O)OR<sub>61</sub>, wherein

R<sub>61</sub> is hydrogen or 1-7C-alkyl,

R7 is hydrogen, halogen, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy or 3-7C-cycloalkylmethoxy,

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

4. (Currently amended) A compound ~~Compounds~~ of the formula I according to claim 1 ~~[[or 3]]~~, in which

- R1 is 1-2C-alkoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R2 is 1-2C-alkoxy, or completely or predominantly fluorine-substituted 1-2C-alkoxy,
- R3 is hydrogen,
- R31 is hydrogen,
- R4 is hydrogen, 1-4C-alkyl, 1-2C-alkoxyethyl or 1-7C-alkylcarbonyl,
- R5 is hydrogen,
- R6 is 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkylethoxy, halogen, nitro, cyano, hydroxyl, 1-4C-alkylcarbonyloxy, mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino, phenoxy or C(O)OR<sub>61</sub>, wherein
- R<sub>61</sub> is hydrogen or 1-7C-alkyl,
- R7 is hydrogen, halogen, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, or 3-7C-cycloalkylmethoxy,

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

5. (Currently amended) A compound ~~Compounds~~ of the formula I according to ~~any of the claims 1, 3, or 4~~ claim 1, in which

R1 is ethoxy, and

R2 is methoxy or difluoromethoxy,

or

R1 is methoxy or difluoromethoxy, and

R2 is methoxy, difluoromethoxy or ethoxy,

or

R1 is difluoromethoxy, and

R2 is methoxy or ethoxy,

or

R1 is methoxy, and

R2 is ethoxy or difluoromethoxy,

R3 is hydrogen,

R31 is hydrogen,

R4 is hydrogen, 1-4C-alkyl, 1-2C-alkoxyethyl or 1-7C-alkylcarbonyl,

R5 is hydrogen,

R6 is 1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 3-7C-cycloalkylmethoxy, halogen, nitro, cyano, hydroxyl, 1-4C-alkylcarbonyloxy,

mono- or di-1-4C-alkylamino, 1-4C-alkylcarbonylamino,  
phenoxy or C(O)OR<sub>61</sub>, wherein

R<sub>61</sub> is hydrogen or 1-7C-alkyl,

R<sub>7</sub> is hydrogen, halogen, 1-4C-alkoxy, completely or  
predominantly fluorine-substituted 1-4C-alkoxy, or 3-7C-  
cycloalkylmethoxy,

~~and the salts, the N-oxides and the salts of the N-oxides of  
these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a  
salt of this compound, an N-oxide of this compound, or a salt of  
an N-oxide of this compound.

6. (Currently amended) A compound ~~Compounds~~ of the formula I  
according to ~~any of the claims 1, 3, 4, or 5~~ claim 1, in which

R<sub>1</sub> is methoxy or difluoromethoxy,

R<sub>2</sub> is methoxy, difluoromethoxy or ethoxy,

R<sub>3</sub> is hydrogen,

R<sub>31</sub> is hydrogen,

R<sub>4</sub> is hydrogen, methyl, ethyl, methoxyethyl or acetyl,

R<sub>5</sub> is hydrogen,

R<sub>6</sub> is methyl, methoxy, ethoxy, propoxy, butoxy,  
difluoromethoxy, trifluoromethoxy, 1,1,2,2-  
tetrafluoroethoxy, cyclopropylmethoxy, fluorine, chlorine,



bromine, nitro, cyano, hydroxyl, acetoxy, dimethylamino, acetamido, phenoxy or C(O)OR<sub>61</sub>, wherein

R<sub>61</sub> is hydrogen or methyl,

R<sub>7</sub> is hydrogen, fluorine, methoxy, ethoxy, propoxy, butoxy, difluoromethoxy or cyclopropylmethoxy,

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

7. (Currently amended) A compound ~~Compounds~~ of the formula I according to ~~any of the claims 1, 3, 4, 5, or 6~~ claim 1, in which

R<sub>1</sub> is methoxy, and

R<sub>2</sub> is methoxy,

or

R<sub>1</sub> is difluoromethoxy, and

R<sub>2</sub> is methoxy,

or

R<sub>1</sub> is methoxy, and

R<sub>2</sub> is ethoxy or difluoromethoxy,

R<sub>3</sub> is hydrogen,

R31 is hydrogen,

R4 is hydrogen, methyl, ethyl, methoxyethyl or acetyl,

R5 is hydrogen,

R6 is methyl, methoxy, ethoxy, propoxy, butoxy,  
difluoromethoxy, trifluoromethoxy, 1,1,2,2-  
tetrafluoroethoxy, cyclopropylmethoxy, fluorine, chlorine,  
bromine, nitro, cyano, hydroxyl, acetoxyl, dimethylamino,  
acetamido, phenoxy or C(O)OR<sub>61</sub>, wherein

R<sub>61</sub> is hydrogen or methyl,

R7 is hydrogen, fluorine, methoxy, difluoromethoxy or  
cyclopropylmethoxy,

~~and the salts, the N-oxides and the salts of the N-oxides of  
these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a  
salt of this compound, an N-oxide of this compound, or a salt of  
an N-oxide of this compound.

8. (Currently amended) A compound ~~Compounds~~ of the formula I  
according to ~~any of the preceding claims~~ claim 1, in which

R1 is methoxy,

R2 is methoxy,

R3 is hydrogen,

R<sub>31</sub> is hydrogen,

R4 is hydrogen or acetyl,

R5 is hydrogen,

R6 is methoxy, cyclopropylmethoxy, nitro, dimethylamino or  
C(O)OR<sub>61</sub>, wherein

R<sub>61</sub> is hydrogen or methyl,

R7 is hydrogen, methoxy or cyclopropylmethoxy,

~~and the salts, the N-oxides and the salts of the N-oxides of  
these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a  
salt of this compound, an N-oxide of this compound, or a salt of  
an N-oxide of this compound.

9. (Currently amended) A compound ~~Compounds~~ according to claim  
1, selected from the group consisting of

(±)-acetic acid (2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxy-  
phenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-  
yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-methoxycarbonylphenyl)-  
8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl  
ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-dimethylaminophenyl)-8,9-  
dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(3,4-dimethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-nitrophenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl ester,

(±)-(2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(4-methoxycarbonylphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(4-dimethylaminophenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(3,4-dimethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(4-nitrophenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(4-carboxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-ol,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-butoxyphenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-8,9-dimethoxy-6-(4-methoxy-phenyl)-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-cyano-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid 4-((2RS,4aRS,10bRS)-2-acetoxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-6-yl)-phenyl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-acetylamino-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-chloro-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(2-chloro-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-8,9-dimethoxy-6-(4-methoxy-3-propoxy-phenyl)-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-8,9-dimethoxy-6-p-tolyl-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-4-((2RS,4aRS,10bRS)-2-acetoxy-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-6-yl)-benzoic acid methyl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-9-ethoxy-6-(4-fluoro-phenyl)-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-cyano-phenyl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(3-cyclopropylmethoxy-4-ethoxy-phenyl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-[3-cyclopropylmethoxy-4-(1,1-difluoro-methoxy)-phenyl]-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-[3,4-bis(1,1-difluoro-methoxy)-phenyl]-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-[3, -(1,1-difluoro-methoxy)-phenyl]-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-9-ethoxy-8-methoxy-6-[4-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-9-ethoxy-8-methoxy-6-(4-trifluoromethoxy-phenyl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-9-ethoxy-6-(3-fluoro-4-methoxy-phenyl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(3,4-difluoro-phenyl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-9-ethoxy-6-(3-fluoro-phenyl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-bromo-phenyl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-[4-(1,1-difluoro-methoxy)-phenyl]-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-8,9-dimethoxy-6-(4-phenoxy-phenyl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-fluoro-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-[3,4-bis-(1,1-difluoro-methoxy)-phenyl]-8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-cyano-phenyl)-8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-4-[(2RS,4aRS,10bRS)-2-acetoxy-8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-benzoic acid methyl ester,

(±)-4-[(2RS,4aRS,10bRS)-2-acetoxy-9-(1,1-difluoro-methoxy)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-benzoic acid methyl ester,

(±)-(2RS,4aRS,10bRS)-6-(4-butoxy-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(4-fluoro-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(±)-N-[4-((2RS,4aRS,10bRS)-2-hydroxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-phenyl]-acetamide,

(±)-(2RS,4aRS,10bRS)-6-(4-chloro-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(2-chloro-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-8,9-dimethoxy-6-(4-methoxy-3-propoxy-phenyl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-[4-(1,1-difluoro-methoxy)-phenyl]-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,

(±)-4-((2RS,4aRS,10bRS)-9-ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzoic acid methyl ester,

(±)-(2RS,4aRS,10bRS)-9-ethoxy-6-(4-fluoro-phenyl)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,



(±)-4-((2RS,4aRS,10bRS)-9-ethoxy-2-hydroxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzonitrile,  
(±)-(2RS,4aRS,10bRS)-6-(3-cyclopropylmethoxy-4-ethoxy-phenyl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-6-[3-cyclopropylmethoxy-4-(1,1-difluoromethoxy)-phenyl]-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-6-[3,4-bis-(1,1-difluoromethoxy)-phenyl]-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-6-[3-(1,1-difluoromethoxy)-phenyl]-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-9-ethoxy-8-methoxy-6-[4-(1,1,2,2-tetrafluoroethoxy)-phenyl]-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-9-ethoxy-8-methoxy-6-(4-trifluoromethoxyphenyl)-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-9-ethoxy-6-(3-fluoro-4-methoxy-phenyl)-8-methoxy-1,2,3,4,4a,10b-hexhydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-6-(3,4-difluoro-phenyl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexhydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-9-ethoxy-6-(3-fluoro-phenyl)-8-methoxy-1,2,3,4,4a,10b-hexhydro-phenanthridin-2-ol,

(±)-(2RS,4aRS,10bRS)-6-(4-bromo-phenyl)-9-ethoxy-8-methoxy-  
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-8,9-dimethoxy-6-p-tolyl-1,2,3,4,4a,10b-  
hexhydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-8,9-dimethoxy-6-(4-phenoxy-phenyl)-  
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-(2RS,4aRS,10bRS)-8,9-dimethoxy-6-(4-methoxy-phenyl)-  
1,2,3,4,4a,10b-hexahydro-phenanthridin-2-ol,  
(±)-4-((2RS,4aRS,10bRS)-2-hydroxy-8,9-dimethoxy-1,2,3,4,4a,10b-  
hexahydro-phenanthridin-6-yl)-benzonitrile,  
(±)-(2RS,4aRS,10bRS)-6-[3,4-bis-(1,1-difluoro-methoxy)-phenyl]-  
8-(1,1-difluoro-methoxy)-9-methoxy-1,2,3,4,4a,10b-hexahydro-  
phenanthridin-2-ol,  
(±)-4-[(2RS,4aRS,10bRS)-8-(1,1-difluoro-methoxy)-2-hydroxy-9-  
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-  
benzonitrile,  
(±)-4-[(2RS,4aRS,10bRS)-8-(1,1-difluoro-methoxy)-2-hydroxy-9-  
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-benzoic  
acid methyl ester,  
(±)-4-[(2RS,4aRS,10bRS)-9-(1,1-difluoro-methoxy)-2-hydroxy-8-  
methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl]-benzoic  
acid methyl ester,

(±)-acetic acid (2RS,4aRS,10bRS)-6-(4-hydroxy-phenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-2-yl ester,

(±)-4-((2RS,4aRS,10bRS)-2-acetoxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzoic acid hydrochloride,

(±)-4-((2RS,4aRS,10bRS)-2-acetoxy-9-(1,1-difluoro-methoxy)-8-methoxy-1,2,3,4,4a,10b-hexahydro-phenanthridin-6-yl)-benzoic acid,

(±)-(2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxy-phenyl)-2,8,9-trimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridine,

(±)-(2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxy-phenyl)-2-ethoxy-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydro-phenanthridine,

[[and]]


(±)-(2RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxy-phenyl)-8,9-dimethoxy-2-(2-methoxy-ethoxy)-1,2,3,4,4a,10b-hexahydro-phenanthridine,

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

the hydrates, solvates, salts, hydrates of the salts and solvates of the salts of these compounds, the N-oxides of these compounds, and the salts of the N-oxides of these compounds.

10. (Currently amended) A compound ~~Compounds~~ of the formula I according to ~~any of the claims 1 to 8~~ claim 1, in which the hydrogen atoms in positions 4a and 10b are in the cis position relative to one another, and ~~the salts, the N-oxides and the salts of the N-oxides of these compounds~~  
or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

11. (Currently amended) A compound ~~Compounds~~ of the formula I according to ~~any of the claims 1 to 8, which have~~ claim 1, which has with respect to the positions 4a and 10b, the configuration shown in formula I\*:






(I\*)

~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

12. (Currently amended) A compound ~~Compounds~~ of the formula I according to ~~any of the claims 1 to 8, which have~~ claim 1, which has with respect to the positions 2, 4a and 10b, the configuration shown either in formula I\*\*, I\*\*\* or I\*\*\*\*:






~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

13. (Currently amended) A compound ~~Compounds~~ of the formula I according to ~~any of the claims 1 to 8, which have~~ claim 1, which has with respect to the position 2, 4a, and 10b, the configuration shown in formula I\*\*\*\*\*:



~~and the salts, the N-oxides and the salts of the N-oxides of these compounds~~

or a hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.

14. (Canceled)

15. (Currently amended) A pharmaceutical composition comprising one or more compounds of the formula I as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, a pharmaceutically acceptable N-oxide of this compound, or a salt of said N-oxide, together with a customary pharmaceutical excipients ~~and/or vehicles~~ auxiliary and/or excipient.

16. (Canceled)

17. (Canceled)

18. (Currently amended) A method for treating ~~illnesses~~ an illness treatable by administration of a PDE inhibitor in a patient comprising administering to said patient a therapeutically effective amount of a compound of the formula I as claimed in claim 1, or a pharmaceutically acceptable hydrate,



solvate, salt, hydrate of a salt or solvate of a salt of this compound, a pharmaceutically acceptable N-oxide of this compound, or a salt of said N-oxide.

19. (Currently amended) A method for treating an airway disorder ~~disorders~~ in a patient comprising administering to said patient a therapeutically effective amount of a compound of the formula I as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, a pharmaceutically acceptable N-oxide of this compound, or a salt of said N-oxide.

20. (New) A method for treating dermatoses in a patient comprising administering to said patient a therapeutically effective amount of a compound of the formula I as claimed in claim 1, or a pharmaceutically acceptable hydrate, solvate, salt, hydrate of a salt or solvate of a salt of this compound, a pharmaceutically acceptable N-oxide of this compound, or a salt of said N-oxide.